Hybrid antibodies

Details Hybrid antibodies Hybrid antibodies

2010-09-17

2011-11-29

Bristol, Lynn (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C530S387300

Reexamination Certificate

active

08067167

ABSTRACT:
Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.

REFERENCES:
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5908925 (1999-06-01), Cohen et al.
patent: 6254868 (2001-07-01), Leung et al.
patent: 7321026 (2008-01-01), Leung
patent: 7399594 (2008-07-01), Rother et al.
patent: 2002/0177170 (2002-11-01), Luo et al.
patent: 2003/0040606 (2003-02-01), Leung
patent: 2003/0109680 (2003-06-01), Wong et al.
patent: 2003/0190705 (2003-10-01), Wong et al.
patent: 0 939 127 (1999-09-01), None
patent: WO 97/49429 (1997-12-01), None
patent: WO 03/002607 (2003-01-01), None
patent: WO 03/025019 (2003-03-01), None
Baca, M. et al., “Antibody Humanization Using Monovalent Phage Display,” J. Biol. Chem., 272(16):10678-10684 (1997).
Benhar, I. et al., “Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38,” Proc. Natl. Acad. Sci. USA, 91:12051-12055 (1994).
Chothia, C., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., 196(4):901-17 (1987).
Couto, J., et al., “Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization,” Cancer Res., 55:1717-1722 (1995).
Foote, J., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J. Mol. Biol., 224(2):487-99 (1992).
Harris et al., “Profiles for the Analysis of Immunoglobulin Sequences: Comparison of V Gene Subgroups,” Protein Science, vol. 4, pp. 306-310 (1995).
Jones, PT., “Replacing ttie Complementaryity-Determining Regions in a Human Antibody With Those From a Mouse,” Nature, 321(6069):522-5 (1986).
Leung et al., “Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific Leukemia/Lymphoma Antibody, LL2,” Mol. Immunol., 31:17-18 (1995).
Leung, S-O., et al., “Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific Leukemia/Lymphoma Antibody, LL2,” Mol. Immunol., 32(17/18):1413-1427 (1995).
Ohtomo, T., et al. “Humanization of Mouse ONS-M21 Antibody with the aid of hybrid variable regions,” Mol. Immunol., 32(6):407-416 (1995).
Qu et al., “Humanization of Immun31, an α-Fetoprotein-specific Antibody,” Clinical Cancer Research, The American Association for Cancer Research, 5(10):3095s-3100s (1999).
Radar, C. et al. “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,” Proc. Natl. Acad. Sci. USA, 95:8910-8915 (1998).
Reichmann, L., et al., “Reshaping Human Antibodies for Therapy,” Nature, 332:323-327 (1988).
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” Journal of Biological Chemistry, 271(37):22611-22618 (1996).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982).
Santos, A.D., “Development of More Efficacious Antibody for Medical Therapy and Diagnosis,” Prog. Nucleic Acid Res. Mol. Biol., 60:164-94 (1998).
Sato, K., “Humanization of a Mouse Anti-Human Interleukin-6 Receptor Antibody Comparing Two Methods for Selecting Human Framework Regions,” Immunol., 31(5):371-81 (1995).
Takeda, S., “Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequence,” Nature, 314 (6010):452-4 (1985).
Yelton et al., “Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codo Based Mutagenesis,” The Journal of Immunology, pp. 1994-2004 (1995).

Affiliated with

Also associated with

Rating

Hybrid antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybrid antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4290238